<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788810</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02116-33</org_study_id>
    <nct_id>NCT04788810</nct_id>
  </id_info>
  <brief_title>Toxicokinetic Study of Dichlorobisphenol A After an Oral or Dermal Single Dose in Healthy Volunteer.</brief_title>
  <acronym>PRECEPT</acronym>
  <official_title>Toxicokinetic Study of Dichlorobisphenol A After an Oral or Dermal Single Dose in Healthy Volunteer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine toxicokinetic parameters of deuterated d12-Cl2BPA&#xD;
      after the administration of a single low dose (50 µg/kg) to healthy volunteers via oral or&#xD;
      dermal routes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dichlorobisphenol A (Cl2BPA)is formed by the reaction of chlorine with bisphenol A present in&#xD;
      water during water disinfection process. As a consequence, Cl2BPA is present in various&#xD;
      aqueous media including tap water. Cl2BPA has also been found in human, in blood, urine,&#xD;
      breast milk and adipose tissue suggesting chronic exposure to this compound. Cl2BPA is an&#xD;
      endocrine disruptor that binds to estrogenic and PPAR-γ receptors. Epidemiological studies&#xD;
      have shown that exposure to DCBPA has been related to the occurrence of diabetes, obesity and&#xD;
      myocardial infarction.&#xD;
&#xD;
      Currently, no toxicokinetic data are available to estimate the disposition (ADME) of Cl2BPA&#xD;
      after oral and dermal exposure in human while these data are needed for proper risk&#xD;
      assessment of this compound.&#xD;
&#xD;
      The objective of this study is to determine toxicokinetic parameters of deuterated d12-Cl2BPA&#xD;
      after the administration of a single low dose (50 µg/kg) to healthy volunteers via oral or&#xD;
      dermal routes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Oral route = 6 volunteers Dermal route = 6 volunteers</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Hour 0-Hour 24</time_frame>
    <description>Non-compartmental and compartmental toxicokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0-Hour 24</time_frame>
    <description>Non-compartmental and compartmental toxicokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total clearance</measure>
    <time_frame>Hour 0 - Hour 24</time_frame>
    <description>Non-compartmental and compartmental toxicokinetic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>Hour 0 - Hour 24</time_frame>
    <description>Non-compartmental and compartmental toxicokinetic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary toxicokinetic parameters</measure>
    <time_frame>Hour 0 - Hour 24</time_frame>
    <description>half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pharmacokinetic Study</condition>
  <arm_group>
    <arm_group_label>Oral route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receiving d12-Cl2BPA via oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermal route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receiving d12-Cl2BPA via oral route</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of d12-Cl2BPA</intervention_name>
    <description>Administration of d12-Cl2BPA</description>
    <arm_group_label>Dermal route</arm_group_label>
    <arm_group_label>Oral route</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-51 year old&#xD;
&#xD;
          -  No current disease&#xD;
&#xD;
          -  BMI range: 18.5-24.9 kg/m²,&#xD;
&#xD;
          -  Non smoker&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
          -  Normal hepatic function&#xD;
&#xD;
          -  Normal gastrointestinal function&#xD;
&#xD;
          -  Affiliated to national health insurance&#xD;
&#xD;
          -  Having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal function ≤ 90 ml/min/1.73 m² (CKD-EPI)&#xD;
&#xD;
          -  Altered hepatic function ASAT &gt; 50 UI/L and/or ALAT &gt; 50 UI/L,&#xD;
&#xD;
          -  Current disease,&#xD;
&#xD;
          -  Heavy alcohol consumption&#xD;
&#xD;
          -  No treatment susceptible to alter Cl2BPA toxicokinetics (drugs that interact with&#xD;
             metabolic enzymes or transporter proteins,, anti-acids, etc)&#xD;
&#xD;
          -  Pregnant women, lactating mothers and women of childbearing potential with no reliable&#xD;
             medical contraception&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Venisse, PhD, PharmD</last_name>
    <phone>+33549444980</phone>
    <email>nicolas.venisse@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIC Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PJ SAULNIER, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toxicokinetics</keyword>
  <keyword>Endocrine Disruptors</keyword>
  <keyword>Bisphenol A derivatives</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

